In order to confirm the results of Thornton and colleagues [25] in our CRC model, we investigated the effect of p38α pharmacological inhibition (with the selective inhibitor ralimetinib) or genetic ablation (with a specific siRNA) on the regulation of the GSK3β phospho-inhibition signal (p-GSK3β T390) (Additional file 1: Fig. S1A, B). Here, GSK3B is linked to colorectal carcinoma.